 Shares of Sesen Bio Inc. NASDAQ: SESN were trading sharply higher following a company announcement that the FDA granted its request for a Type A Meeting to discuss the issues brought up within the complete response letter CRL response to Vicineum. Sesen Bio received a CRL response to their bladder cancer candidate Vicineum back on August 16th due to a combination of manufacturing issues and requests for additional data and statistical analyses. 